GlassScriptPhysician profile
Robert C Knapp
NPI 1437268067
$13,405.88
in general payments reported to CMS, 2019-2025
60 companies · $1,829 in 2025
The $1,829 reported for 2025 was more than what 75% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,306 · 2020: $1,090 · 2021: $1,733 · 2022: $2,091 · 2023: $2,082 · 2024: $2,275 · 2025: $1,829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,117 · Education: $69.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,116.78 |
| Education | $69.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $1,571.84 | 2019-2025 | Unithroid |
| Abbvie INC. | $1,228.94 | 2019-2025 | |
| Lilly USA, LLC | $918.17 | 2019-2025 | Jardiance, Mounjaro, Humulin |
| Novo Nordisk INC | $748.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $691.57 | 2019-2025 | Repatha, Tepezza, Repatha |
| Astrazeneca Pharmaceuticals LP | $590.94 | 2019-2025 | Farxiga, Breztri |
| Amarin Pharma, INC. | $587.70 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $471.84 | 2019-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $441.66 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $397.31 | 2019-2023 | |
| Glaxosmithkline, LLC. | $384.60 | 2019-2025 | Trelegy Ellipta |
| Medtronic, INC. | $359.54 | 2021-2025 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $337.65 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Amphastar Pharmaceuticals, INC. | $318.19 | 2024-2025 | |
| Corcept Therapeutics | $293.11 | 2019-2025 | Korlym |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Knapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.